6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
intolerance	NN	intolerance	intolerance	intoler	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
1%	CD	1%	1%	1%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
treatment	NN	treatment	treatment	treatment	N	O
are	VBP	are	are	are	N	O
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
transaminases	VBZ	transaminases	transaminase	transaminas	Y	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
fever	RB	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
local	JJ	local	local	local	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
1%	CD	1%	1%	1%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
transaminases	VBZ	transaminases	transaminase	transaminas	Y	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
fever	RB	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
local	JJ	local	local	local	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	JJ	contact	contact	contact	N	O
Jazz	NNP	jazz	jazz	jazz	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
520	CD	520	520	520	N	O
-	:	-	-	-	N	O
5568	CD	5568	5568	5568	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
widely	RB	widely	widely	wide	N	O
varying	JJ	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
presented	VBN	presented	presented	present	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
information	NN	information	information	inform	N	O
collected	VBN	collected	collected	collect	N	O
from	IN	from	from	from	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	O
-	:	-	-	-	N	O
center	NN	center	center	center	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
pharmacology	NN	pharmacology	pharmacology	pharmacolog	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
administration	NN	administration	administration	administr	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
Master	NNP	master	master	master	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Protocol	NNP	protocol	protocol	protocol	N	O
(	(	(	(	(	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
expanded	JJ	expanded	expanded	expand	N	O
access	NN	access	access	access	N	O
program	NN	program	program	program	N	O
(	(	(	(	(	N	O
both	DT	both	both	both	N	O
intramuscular	NN	intramuscular	intramuscular	intramuscular	N	O
,	,	,	,	,	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
or	CC	or	or	or	N	O
unknown	JJ	unknown	unknown	unknown	N	O
administration	NN	administration	administration	administr	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	O
-	:	-	-	-	N	O
center	NN	center	center	center	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
(	(	(	(	(	N	O
PK	NNP	pk	pk	pk	N	O
)	)	)	)	)	N	O
study	VBP	study	study	studi	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
.	.	.	.	.	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
58	CD	58	58	58	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
on	IN	on	on	on	N	O
National	NNP	national	national	nation	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Institute	NNP	institute	institute	institut	N	O
(	(	(	(	(	N	O
NCI	NNP	nci	nci	nci	N	O
)-	NNP	)-	)-	)-	N	O
sponsored	VBD	sponsored	sponsored	sponsor	N	O
cooperative	JJ	cooperative	cooperative	cooper	N	O
group	NN	group	group	group	N	O
ALL	NNP	all	all	all	N	O
protocols	NNS	protocols	protocol	protocol	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
unable	JJ	unable	unable	unabl	N	O
to	TO	to	to	to	N	O
continue	VB	continue	continue	continu	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
pegaspargase	NN	pegaspargase	pegaspargase	pegaspargas	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
6	CD	6	6	6	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
International	NNP	international	international	intern	N	O
Units	NNP	units	unit	unit	N	O
m	VBD	m	m	m	N	O
2	CD	2	2	2	N	O
intramuscularly	RB	intramuscularly	intramuscularly	intramuscularli	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
Monday	NNP	monday	monday	monday	N	O
,	,	,	,	,	N	O
Wednesday	NNP	wednesday	wednesday	wednesday	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Friday	NNP	friday	friday	friday	N	O
schedule	NN	schedule	schedule	schedul	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
replacement	NN	replacement	replacement	replac	N	O
for	IN	for	for	for	N	O
each	DT	each	each	each	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
pegaspargase	NN	pegaspargase	pegaspargase	pegaspargas	N	O
remaining	VBG	remaining	remaining	remain	N	O
on	IN	on	on	on	N	O
their	PRP$	their	their	their	N	O
original	JJ	original	original	origin	N	O
treatment	NN	treatment	treatment	treatment	N	O
protocol	NN	protocol	protocol	protocol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
population	NN	population	population	popul	N	O
included	VBD	included	included	includ	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
11	CD	11	11	11	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
59%	CD	59%	59%	59%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
78%	CD	78%	78%	78%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
10%	CD	10%	10%	10%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
5%	CD	5%	5%	5%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
were	VBD	were	were	were	N	O
other	JJ	other	other	other	N	O
or	CC	or	or	or	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
35%	CD	35%	35%	35%	N	O
were	VBD	were	were	were	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
or	CC	or	or	or	N	O
Latino	NNP	latino	latino	latino	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
courses	NNS	courses	course	cours	N	O
ranged	VBD	ranged	ranged	rang	N	O
from	IN	from	from	from	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
9	CD	9	9	9	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
76%	CD	76%	76%	76%	N	O
(	(	(	(	(	N	O
44	CD	44	44	44	N	O
of	IN	of	of	of	N	O
58	CD	58	58	58	N	O
)	)	)	)	)	N	O
completed	VBN	completed	completed	complet	N	O
all	DT	all	all	all	N	O
planned	VBN	planned	planned	plan	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Fourteen	NNP	fourteen	fourteen	fourteen	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
stopped	VBD	stopped	stopped	stop	N	O
therapy	RB	therapy	therapy	therapi	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
completion	NN	completion	completion	complet	N	O
;	:	;	;	;	N	O
seven	CD	seven	seven	seven	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
five	CD	five	five	five	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
physician	JJ	physician	physician	physician	N	O
or	CC	or	or	or	N	O
patient	JJ	patient	patient	patient	N	O
choice	NN	choice	choice	choic	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
disease	VB	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
during	IN	during	during	dure	N	O
frontline	JJ	frontline	frontline	frontlin	N	O
protocol	NN	protocol	protocol	protocol	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
was	VBD	was	wa	wa	N	O
continued	VBN	continued	continued	continu	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
prescribed	JJ	prescribed	prescribed	prescrib	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
30	CD	30	30	30	N	O
patients	NNS	patients	patient	patient	N	O
[	JJ	[	[	[	N	O
29	CD	29	29	29	N	O
were	VBD	were	were	were	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
ALL	DT	all	all	all	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
for	IN	for	for	for	N	O
lymphoblastic	JJ	lymphoblastic	lymphoblastic	lymphoblast	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
(	(	(	(	(	N	O
LBL	NNP	lbl	lbl	lbl	N	O
)]	NNP	)]	)]	)]	N	O
following	VBG	following	following	follow	N	O
allergy	NN	allergy	allergy	allergi	Y	O
to	TO	to	to	to	N	O
native	VB	native	native	nativ	N	O
E.	NNP	e.	e.	e.	N	O
coli	JJ	coli	coli	coli	N	O
asparaginase	NN	asparaginase	asparaginase	asparaginas	N	O
or	CC	or	or	or	N	O
pegaspargase	NN	pegaspargase	pegaspargase	pegaspargas	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
International	NNP	international	international	intern	N	O
Unit	NNP	unit	unit	unit	N	O
m	VBZ	m	m	m	N	O
2	CD	2	2	2	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
administered	VBN	administered	administered	administ	N	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
Monday	NNP	monday	monday	monday	N	O
,	,	,	,	,	N	O
Wednesday	NNP	wednesday	wednesday	wednesday	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Friday	NNP	friday	friday	friday	N	O
schedule	NN	schedule	schedule	schedul	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
doses	NNS	doses	dos	dose	N	O
)	)	)	)	)	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
replacement	NN	replacement	replacement	replac	N	O
for	IN	for	for	for	N	O
doses	NNS	doses	dos	dose	N	O
remaining	VBG	remaining	remaining	remain	N	O
on	IN	on	on	on	N	O
their	PRP$	their	their	their	N	O
original	JJ	original	original	origin	N	O
treatment	NN	treatment	treatment	treatment	N	O
plan	NN	plan	plan	plan	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
population	NN	population	population	popul	N	O
included	VBD	included	included	includ	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
63%	CD	63%	63%	63%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
27%	CD	27%	27%	27%	N	O
were	VBD	were	were	were	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
or	CC	or	or	or	N	O
Latino	NNP	latino	latino	latino	N	O
,	,	,	,	,	N	O
83%	CD	83%	83%	83%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
7%	CD	7%	7%	7%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
were	VBD	were	were	were	N	O
other	JJ	other	other	other	N	O
(	(	(	(	(	N	O
American	JJ	american	american	american	N	O
Indian	NNP	indian	indian	indian	N	O
,	,	,	,	,	N	O
Alaska	NNP	alaska	alaska	alaska	N	O
Native	NNP	native	native	nativ	N	O
or	CC	or	or	or	N	O
Indian	NNP	indian	indian	indian	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
trial	NN	trial	trial	trial	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
1368	CD	1368	1368	1368	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALL	DT	all	all	all	N	O
or	CC	or	or	or	N	O
lymphoblastic	JJ	lymphoblastic	lymphoblastic	lymphoblast	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
after	IN	after	after	after	N	O
developing	VBG	developing	developing	develop	N	O
systemic	JJ	systemic	systemic	system	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
E.	NNP	e.	e.	e.	N	O
coli	SYM	coli	coli	coli	N	O
-	:	-	-	-	N	O
derived	VBN	derived	derived	deriv	N	O
asparaginase	NN	asparaginase	asparaginase	asparaginas	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
1368	CD	1368	1368	1368	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
were	VBD	were	were	were	N	O
received	VBN	received	received	receiv	N	O
for	IN	for	for	for	N	O
940	CD	940	940	940	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
to	TO	to	to	to	N	O
76	CD	76	76	76	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
63%	CD	63%	63%	63%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
91%	CD	91%	91%	91%	N	O
with	IN	with	with	with	N	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
with	IN	with	with	with	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6%	CD	6%	6%	6%	N	O
with	IN	with	with	with	N	O
unknown	JJ	unknown	unknown	unknown	N	O
disease	NN	disease	disease	diseas	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
several	JJ	several	several	sever	N	O
schedules	NNS	schedules	schedule	schedul	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
center	NN	center	center	center	N	O
specifications	NNS	specifications	specification	specif	N	O
with	IN	with	with	with	N	O
doses	NNS	doses	dos	dose	N	O
that	WDT	that	that	that	N	O
ranged	VBD	ranged	ranged	rang	N	O
from	IN	from	from	from	N	O
20	CD	20	20	20	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
to	TO	to	to	to	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
International	NNP	international	international	intern	N	O
Units	NNP	units	unit	unit	N	O
m	VBD	m	m	m	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
route	NN	route	route	rout	N	O
of	IN	of	of	of	N	O
administration	NN	administration	administration	administr	N	O
was	VBD	was	wa	wa	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
n	RB	n	n	n	N	O
852	CD	852	852	852	N	O
,	,	,	,	,	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
n	RB	n	n	n	N	O
29	CD	29	29	29	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
or	CC	or	or	or	N	O
unknown	JJ	unknown	unknown	unknown	N	O
n	JJ	n	n	n	N	O
59	CD	59	59	59	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
planned	JJ	planned	planned	plan	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
ranged	VBD	ranged	ranged	rang	N	O
from	IN	from	from	from	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
48	CD	48	48	48	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

Seventy	NNP	seventy	seventy	seventi	N	O
-	:	-	-	-	N	O
eight	CD	eight	eight	eight	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
693	CD	693	693	693	N	O
of	IN	of	of	of	N	O
893	CD	893	893	893	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
all	DT	all	all	all	N	O
planned	VBN	planned	planned	plan	N	O
doses	NNS	doses	dos	dose	N	O
to	TO	to	to	to	N	O
complete	VB	complete	complete	complet	N	O
their	PRP$	their	their	their	N	O
prescribed	JJ	prescribed	prescribed	prescrib	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
safety	NN	safety	safety	safeti	N	O
information	NN	information	information	inform	N	O
was	VBD	was	wa	wa	N	O
prospectively	RB	prospectively	prospectively	prospect	N	O
and	CC	and	and	and	N	O
systematically	RB	systematically	systematically	systemat	N	O
collected	VBN	collected	collected	collect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
special	JJ	special	special	special	N	O
interest	NN	interest	interest	interest	N	O
:	:	:	:	:	N	O
allergy	NN	allergy	allergy	allergi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
coagulopathy	NN	coagulopathy	coagulopathy	coagulopathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
infarct	NN	infarct	infarct	infarct	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperlipidemia	NN	hyperlipidemia	hyperlipidemia	hyperlipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
CNS	NNP	cns	cns	cn	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
or	CC	or	or	or	N	O
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
only	RB	only	only	onli	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
all	DT	all	all	all	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
were	VBD	were	were	were	N	O
prospectively	RB	prospectively	prospectively	prospect	N	O
collected	VBN	collected	collected	collect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
were	VBD	were	were	were	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
case	NN	case	case	case	N	O
report	NN	report	report	report	N	O
forms	NNS	forms	form	form	N	O
that	WDT	that	that	that	N	O
collected	VBD	collected	collected	collect	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
forms	NNS	forms	form	form	N	B-Factor
specifically	RB	specifically	specifically	specif	N	I-Factor
requested	VBN	requested	requested	request	N	I-Factor
information	NN	information	information	inform	N	I-Factor
on	IN	on	on	on	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
pancreatic	JJ	pancreatic	pancreatic	pancreat	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	NN	hematologic	hematologic	hematolog	N	O
,	,	,	,	,	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
trial	NN	trial	trial	trial	N	O
is	VBZ	is	is	is	N	O
provided	VBN	provided	provided	provid	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	NN	hematologic	hematologic	hematolog	N	O
,	,	,	,	,	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
EMTP	NNP	emtp	emtp	emtp	N	O
trial	NN	trial	trial	trial	N	O
is	VBZ	is	is	is	N	O
provided	VBN	provided	provided	provid	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
6.2	CD	6.2	6.2	6.2	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
most	JJS	most	most	most	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
develop	VB	develop	develop	develop	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
ADA	NNP	ada	ada	ada	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
.	.	.	.	.	N	O
In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
treatment	NN	treatment	treatment	treatment	N	O
by	IN	by	by	by	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
administration	NN	administration	administration	administr	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
of	IN	of	of	of	N	O
56	CD	56	56	56	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
developed	VBD	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
6	CD	6	6	6	N	O
ADA	NNP	ada	ada	ada	N	O
positive	JJ	positive	positive	posit	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
during	IN	during	during	dure	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
56	CD	56	56	56	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
6	CD	6	6	6	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
neutralizing	JJ	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O
In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
treatment	NN	treatment	treatment	treatment	N	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
administration	NN	administration	administration	administr	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
13.3%	CD	13.3%	13.3%	13.3%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
developed	VBD	developed	developed	develop	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
ERWINAZE	NN	erwinaze	erwinaze	erwinaz	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
ERWINAZE	NN	erwinaze	erwinaze	erwinaz	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
experienced	JJ	experienced	experienced	experienc	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
neutralizing	JJ	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O
The	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
ADA	NNP	ada	ada	ada	N	O
to	TO	to	to	to	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
through	IN	through	through	through	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
.	.	.	.	.	N	O
Immunogenicity	NNP	immunogenicity	immunogenicity	immunogen	N	O
assay	VBP	assay	assay	assay	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
:	:	:	:	:	N	O
assay	NN	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
ERWINAZE	VB	erwinaze	erwinaze	erwinaz	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
occur	NN	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
:	:	:	:	:	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
or	CC	or	or	or	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Glucose	JJ	glucose	glucose	glucos	Y	B-AdverseReaction
intolerance	NN	intolerance	intolerance	intoler	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
irreversible	JJ	irreversible	irreversible	irrevers	N	B-Severity
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
:	:	:	:	:	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
until	IN	until	until	until	N	O
resolved	VBN	resolved	resolved	resolv	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
4	CD	4	4	4	N	I-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Administer	RBR	administer	administer	administ	N	O
this	DT	this	this	thi	N	O
product	NN	product	product	product	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
setting	NN	setting	setting	set	N	O
with	IN	with	with	with	N	O
resuscitation	NN	resuscitation	resuscitation	resuscit	Y	O
equipment	NN	equipment	equipment	equip	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
agents	NNS	agents	agent	agent	N	O
necessary	JJ	necessary	necessary	necessari	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Evaluate	JJ	evaluate	evaluate	evalu	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
compatible	JJ	compatible	compatible	compat	N	O
with	IN	with	with	with	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
or	CC	or	or	or	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
manifested	VBN	manifested	manifested	manifest	N	O
by	IN	by	by	by	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
72	CD	72	72	72	N	O
hours	NNS	hours	hour	hour	N	O
and	CC	and	and	and	N	O
amylase	VB	amylase	amylase	amylas	Y	O
elevation	NN	elevation	elevation	elev	N	O
2.0	CD	2.0	2.0	2.0	N	O
x	NN	x	x	x	N	O
ULN	NNP	uln	uln	uln	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
contraindication	NN	contraindication	contraindication	contraind	N	O
to	TO	to	to	to	N	O
additional	JJ	additional	additional	addit	N	O
asparaginase	NN	asparaginase	asparaginase	asparaginas	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
mild	NN	mild	mild	mild	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
,	,	,	,	,	N	O
hold	VBP	hold	hold	hold	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
subside	RB	subside	subside	subsid	N	O
and	CC	and	and	and	N	O
amylase	JJ	amylase	amylase	amylas	Y	O
levels	NNS	levels	level	level	N	O
return	VBP	return	return	return	N	O
to	TO	to	to	to	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O
Intolerance	NNP	intolerance	intolerance	intoler	N	O

Glucose	NNP	glucose	glucose	glucos	Y	O
intolerance	NN	intolerance	intolerance	intoler	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
glucose	VBP	glucose	glucose	glucos	Y	B-AdverseReaction
intolerance	NN	intolerance	intolerance	intoler	N	I-AdverseReaction
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
irreversible	JJ	irreversible	irreversible	irrevers	N	B-Severity
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
insulin	NN	insulin	insulin	insulin	Y	O
therapy	NN	therapy	therapy	therapi	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O
and	CC	and	and	and	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O

Serious	JJ	serious	serious	seriou	N	B-Severity
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
sagittal	JJ	sagittal	sagittal	sagitt	N	B-AdverseReaction
sinus	NN	sinus	sinus	sinu	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
E.	NNP	e.	e.	e.	N	O
coli	NNS	coli	coli	coli	N	O
and	CC	and	and	and	N	O
Erwinia	NNP	erwinia	erwinia	erwinia	N	O
-	:	-	-	-	N	O
derived	VBD	derived	derived	deriv	N	O
L	NNP	l	l	l	N	O
-	:	-	-	-	N	O
asparaginase	NN	asparaginase	asparaginase	asparaginas	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
coagulation	NN	coagulation	coagulation	coagul	N	B-AdverseReaction
proteins	NNS	proteins	protein	protein	N	I-AdverseReaction
were	VBD	were	were	were	N	O
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
after	IN	after	after	after	N	O
a	DT	a	a	a	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
by	IN	by	by	by	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
administration	NN	administration	administration	administr	N	O
:	:	:	:	:	N	O
fibrinogen	NN	fibrinogen	fibrinogen	fibrinogen	Y	I-AdverseReaction
,	,	,	,	,	N	O
protein	JJ	protein	protein	protein	Y	I-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
,	,	,	,	,	N	O
protein	NN	protein	protein	protein	Y	I-AdverseReaction
S	NNP	s	s	s	N	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anti	SYM	anti	anti	anti	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
thrombin	NN	thrombin	thrombin	thrombin	Y	I-AdverseReaction
III	NNP	iii	iii	iii	N	I-AdverseReaction
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
or	CC	or	or	or	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
event	NN	event	event	event	N	O
until	IN	until	until	until	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
;	:	;	;	;	N	O
after	IN	after	after	after	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ERWINAZE	NNP	erwinaze	erwinaze	erwinaz	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
.	.	.	.	.	N	O

